Thyrocare Technologies Ltd. (THYROCARE) fundamentals
Thyrocare Technologies Ltd. is a listed company in Healthcare Services, part of the Healthcare sector, listed on the NSE as THYROCARE (ISIN INE594H01019). This page carries its reported financials, balance sheet, cash flow, shareholding pattern and valuation ratios.
What Thyrocare Technologies Ltd. does
Thyrocare Technologies Limited is an India-based company, which operates as a healthcare services provider. It offers a range of diagnostic and related healthcare tests and services that are focused on early detection, preventive care, and ongoing disease monitoring. Its segments include diagnostic testing services, Imaging Services, and others. The Diagnostic Testing Services segment includes diagnostic and testing services, selling of consumables used for collection and promotion of pathology. The Imaging Services include diagnostic and imaging services, the selling of radiopharmaceuticals, and consumables for reporting. The Others segment includes the sale of testing equipment and consumables, and the selling of glucometer and glucostrips under the brand, Sugarscan. It has a centralized fully automated diagnostic testing laboratory, regional processing laboratories, and a medical cyclotron facility across India. It is also focused on offering pathological services.
Valuation and market data
| Last close | ₹552.70 |
|---|---|
| Market capitalisation | ₹8,764 crore |
| Enterprise value | ₹8,777 crore |
| P/E (TTM) | 53.82 |
| Price to book | 14.96 |
| Price to sales (TTM) | 5.87 |
| Book value per share | ₹36.96 |
| Dividend yield | 253.30% |
| Sector | Healthcare |
| Industry | Healthcare Services |
| Listed since | Mon May 09 |
Annual results
| Period | Revenue | Profit before tax | Net profit | EPS |
|---|---|---|---|---|
| Mar 2026 | ₹788 crore | ₹210 crore | ₹149 crore | 9.36 |
| Mar 2025 | ₹646 crore | ₹151 crore | ₹96 crore | 5.98 |
| Mar 2024 | ₹531 crore | ₹98 crore | ₹71 crore | 13.44 |
| Mar 2023 | ₹492 crore | ₹81 crore | ₹57 crore | 10.77 |
Figures are as reported (standalone), in ₹ crore.
Shareholding pattern
As of Jun 2026:
| Promoters | 60.9% |
|---|---|
| Foreign institutions (FII) | 5.4% |
| Mutual funds | 19.9% |
| Other domestic institutions | 1.1% |
| Retail and others | 12.7% |
More on BreakPoint
FundaX company research covers every listed company with reported financials. BreakPoint Pro adds the BreakPoint iQ score, the screener and the multibagger board.
Data is sourced from exchange filings and vendor feeds and is for research, not investment advice. Figures can be restated by the company after publication.